Elutia Inc. (ELUT)

Market Cap	38.36M
Revenue (ttm)	23.68M
Net Income (ttm)	-21.32M
Shares Out	42.40M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	394,677
Open	0.8913
Previous Close	0.8900
Day's Range	0.8816 - 0.9846
52-Week Range	0.8500 - 5.1200
Beta	0.78
Analysts	Strong Buy
Price Target	7.00 (+673.57%)
Earnings Date	Nov 13, 2025

About ELUT

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women’s Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides Prox...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 8, 2020
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: ELUT
• Website: https://elutia.com

Financial Performance

In 2024, Elutia's revenue was $24.38 million, a decrease of -1.50% compared to the previous year's $24.75 million. Losses were -$53.95 million, 43.3% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for ELUT stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 673.57% from the latest price.

Price Target

$7.0

(673.57% upside)

Analyst Consensus: Strong Buy